Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Xbiotech Inc (XBIT)

Xbiotech Inc (XBIT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study

Novel Natrunix Treatment Shows Promise in Combination Chemotherapy for Treatment of Pancreatic Cancer...

XBIT : 7.91 (-2.47%)
Oversold Conditions For XBiotech (XBIT)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

XBIT : 7.91 (-2.47%)
XBiotech Inks Clinical Manufacturing Deal

XBiotech Manufacturing Antibody Drug for Janssen Research & Development, LLC (Janssen), One of the Janssen Pharmaceutical Companies of Johnson & Johnson...

XBIT : 7.91 (-2.47%)
XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ

Natrunix-SQ, A True Human Antibody Therapy Discovered and Manufactured at XBiotech, Is Aimed as a Breakthrough Treatment for Arthritic Disease...

XBIT : 7.91 (-2.47%)
XBiotech to Launch Novel Candidate Therapy for Stroke

Company Commencing Phase I/II Study to Test Safety and Efficacy of its New Drug Candidate to Reduce Brain Injury After Stroke...

XBIT : 7.91 (-2.47%)
Dr. Benjamin Musher to Chair Phase 1-2 Study Evaluating XBiotech’s Natrunix™ Anti-Cancer Therapy in Pancreatic Cancer

AUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced that Benjamin Musher M.D., will chair XBiotech’s clinical program for pancreatic cancer....

XBIT : 7.91 (-2.47%)
XBiotech Announces Addition of Dr. Mark Ziats, M.D. Ph.D. as Medical Director

Dr. Ziats Joins Clinical Team Involved in Launch and Management of Clinical Studies Across Multiple Indications

XBIT : 7.91 (-2.47%)
XBiotech Announces Payment of Dividend to Holders of Common Stock

Company distributed USD $75 Million to Shareholders

XBIT : 7.91 (-2.47%)
XBiotech Announces Dividend to Holders of Common Stock

AUSTIN, Texas, July 06, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc.’s (NASDAQ: XBIT) (“XBiotech”) Board of Directors has declared an extraordinary cash dividend of approximately $2.50 per share, or...

XBIT : 7.91 (-2.47%)
XBiotech Announces Receipt of $75 Million from Sale of Antibody

Company Has Now Received a Total of $750 million for Sale of Its True Human Antibody

XBIT : 7.91 (-2.47%)

Barchart Exclusives

3 Energy Dividend Stocks Leading the S&P 500 Higher
These three energy dividend stocks have outperformed the S&P 500 on a year-to-date basis, and rank among the index's top 20 performers of 2024 so far. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar